Bone Biologics Corp
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
BBLG$0.33+3.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a) The following documents are filed as part of this report:
(1) Financial Statements:
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 572) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations | F-4 |
| Consolidated Statements of Stockholders’ Deficit | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
(2) Financial Statement Schedules:
All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.
(3) Exhibits. The following is a list of exhibits filed as part of this Annual Report on Form 10-K.
| Exhibit · Incorporated by reference (unless otherwise indicated) | |||||
|---|---|---|---|---|---|
| Number | Exhibit Title | Form | File | Exhibit | Filing date |
| 2.1 | Agreement and Plan of Merger, dated as of September 19, 2014, by and among AFH Acquisition X, Inc., Bone Biologics Acquisition Corp., and Bone Biologics, Inc. | 8-K | 000-53078 | 2.1 | September 25, 2014 |
| 2.2 | Certificate of Merger as filed with the California Secretary of State effective September 19, 2014 | 8-K | 000-53078 | 2.2 | September 25, 2014 |
| 3.1 | Amended and Restated Certificate of Incorporation of Bone Biologics Corporation | 8-K | 000-53078 | 3.1(i) | September 25, 2014 |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bone Biologics Corporation | 8-K | 000-53078 | 3.1 | October 15, 2021 |
| 3.3 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bone Biologics Corporation | 8-K | 001-40899 | 3.1 | June 6, 2023 |
| 3.4 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bone Biologics Corporation | 8-K | 001-40899 | 3.1 | December 18, 2023 |
| 3.5 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed June 5, 2025 | 8-K | 001-40899 | 3.1 | June 6, 2025 |
| 3.6 | Amended and Restated Bylaws of Bone Biologics Corporation | 8-K | 001-40899 | 3.1 | March 8, 2022 |
| 3.7 | Amendment No. 1 to the Amended and Restated Bylaws of Bone Biologics Corporation | 8-K | 001-40899 | 3.1 | October 24, 2023 |
| 4.1 | Warrant Agent Agreement between the Company and Equiniti Trust Company dated as of October 13, 2021 | 8-K | 000-53078 | 4.1 | October 15, 2021 |
| 4.2 | Form of Warrant (October 2021) | S-1 | 333-276771 | 4.2 | January 30, 2024 |
| 4.3 | Form of Representative’s Warrant (October 2021) | 8-K | 000-53078 | 1.1 | October 15, 2021 |
| 4.4 | Warrant Agent Agreement between the Company and Equiniti Trust Company dated as of October 7, 2022 | 8-K | 001-40899 | 4.1 | October 11, 2022 |
| 4.5 | Form of Series A Warrant (October 2022) | S-1 | 333-276771 | 4.5 | January 30, 2024 |
| 4.6 | Form of Series B Warrant (October 2022) | S-1 | 333-276771 | 4.6 | January 30, 2024 |
| 4.7 | Form of Series C Warrant (October 2022) | S-1 | 333-276771 | 4.7 | January 30, 2024 |
| 4.8 | Form of Representative’s Warrant (October 2022) | 8-K | 001-40899 | 1.1 | October 11, 2022 |
| 4.9 | Form of Warrant (November 2023) | S-3 | 333-276412 | 4.1 | January 5, 2024 |
| 4.10 | Form of Placement Agent Warrant (November 2023) | 8-K | 001-40899 | 4.2 | November 20, 2023 |
| 4.11 | Form of Warrant dated March 6, 2024 | 8-K | 001-40899 | 4.1 | March 6, 2024 |
| 4.12 | Form of Placement Agent Warrant dated March 6, 2024 | 8-K | 001-40899 | 4.3 | March 6, 2024 |
| 4.13 | Form of New Warrant dated August 2, 2024 | 8-K | 001-40899 | 4.1 | August 2, 2024 |
| 4.14 | Form of Placement Agent Warrant dated August 2, 2024 | 8-K | 001-40899 | 4.2 | August 2, 2024 |
| 4.15 | Form of Series D Warrant dated June 30, 2025 | 8-K | 001-40899 | 4.1 | June 30, 2025 |
| 4.16 | Form of Series E Warrant dated June 30, 2025 | 8-K | 001-40899 | 4.2 | June 30, 2025 |
| 4.17 | Form of Placement Agent Warrant dated June 30, 2025 | 8-K | 001-40899 | 4.4 | June 30, 2025 |
| 4.18* | Description of Securities | - | - | - | - |
| 10.1+ | Director Offer Letter, dated July 1, 2014, by and between Bruce Stroever and Bone Biologics Corporation | 8-K | 000-53078 | 10.4 | September 25, 2014 |
| 10.2+ | Form of Indemnification Agreement | S-1 | 333-276771 | 10.2 | January 30, 2024 |
| 10.3+ | Amended and Restated Employment Agreement, dated January 1, 2024, by and between Bone Biologics Corporation and Jeffrey Frelick | 10-Q | 001-40899 | 10.2 | May 14, 2024 |
| 10.4+ | Employment Agreement dated December 17, 2021 between the Company and Deina Walsh | 8-K | 001-40899 | 10.1 | December 22, 2021 |
| 10.5+ | Amendment No. 1 to Employment Agreement dated December 17, 2021 between the Company and Deina Walsh | 10-Q | 001-40899 | 10.3 | May 14, 2024 |
| 10.6+ | Bone Biologics Corporation Non-Employee Director Compensation Policy | 8-K | 000-53078 | 10.1 | January 4, 2016 |
| 10.7+ | Bone Biologics Corporation 2015 Equity Incentive Plan | 8-K | 000-53078 | 10.3 | January 4, 2016 |
| 10.8+ | First Amendment to the Bone Biologics Corporation 2015 Equity Incentive Plan | Schedule 14A | 001-40899 | Appendix B | August 3, 2023 |
| 10.9+ | Second Amendment to the Bone Biologics Corporation 2015 Equity Incentive Plan | 8-K | 001-40899 | 10.1 | May 30, 2025 |
| 10.10+ | Form of Stock Option Grant Notice and Option Agreement for the Bone Biologics Corporation 2015 Equity Incentive Plan | 8-K | 000-53078 | 10.4 | January 4, 2016 |
| 10.11+ | Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement | 8-K | 000-53078 | 10.5 | January 4, 2016 |
| 10.12 | Amended and Restated Exclusive License Agreement, dated as of March 21, 2019, by and between the Company and The Regents of the University of California | 8-K | 000-53078 | 10.1 | April 16, 2019 |
| 10.13 | First Amendment to the Amended License Agreement dated August 13, 2020 between the Company and the Regents of the University of California | S-1/A | 333-257484 | 10.40 | October 7, 2021 |
| 10.14 | Third Amendment to the Amended License Agreement dated June 8, 2022 between the Company and the Regents of the University of California | 8-K | 001-40899 | 10.1 | June 9, 2022 |
| 10.15 | Supply and Development Support Agreement dated March 3, 2022 between the Company and Musculoskeletal Transplant Foundation, Inc. | 10-K | 001-40899 | 10.30 | March 15, 2022 |
| 10.16 | At The Market Offering Agreement, dated September 27, 2024, by and between Bone Biologics Corporation and H.C. Wainwright & Co., LLC | 8-K | 001-40899 | 1.1 | September 27, 2024 |
| 10.17 | Form of Securities Purchase Agreement dated June 27, 2025 | 8-K | 001-40899 | 10.1 | June 30, 2025 |
| 19.1 | Bone Biologics Corporation Insider Trading Policy | 10-K | 001-40899 | 19.1 | February 26, 2025 |
| 21.1* | List of Subsidiaries | — | — | — | — |
| 23.1* | Consent of Independent Registered Public Accounting Firm, Weinberg & Company, P.A. | — | — | — | — |
| 24* | Power of Attorney (included in signature page hereto) | — | — | — | — |
| 31.1* | Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-K for the year ended December 31, 2025. | — | — | — | — |
| 31.2* | Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-K for the year ended December 31, 2025. | — | — | — | — |
| 32.1** | Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | — | — | — | — |
| 32.2** | Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | — | — | — | — |
| 97 | Policy for the Recovery of Erroneously Awarded Compensation | 10-K | 001-40899 | 97 | February 21, 2024 |
| 101.INS* | Inline XBRL Instance Document | — | — | — | — |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | — | — | — | — |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | — | — | — | — |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | — | — | — | — |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | — | — | — | — |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | — | — | — | — |
| 104* | Cover Page formatted in Inline XBRL and contained in Exhibit 101 | ||||
- Filed herewith.
** Furnished herewith.
- Management contract or compensatory arrangement.
± Certain information has been omitted from this exhibit in reliance upon Item 601(a)(5) of Regulation S-K and will be furnished to the Securities and Exchange Commission upon request.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.